Evotec SEXSWX:EVT +4.02%68 Days Inventory is 18.18 as of Mar. 2026, which is 29% above its 10-year median of 14.11. GuruFocus rates XSWX:EVT with a GF Score™ of 68/100 and a GF Value™ of CHF6.99 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 916 Drug Manufacturers companies, Evotec SE ranks better than 98.58% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Evotec SE's Average Total Inventories for the
three
months ended in Mar. 2026 was CHF28.7 Mil. Evotec SE's Cost of Goods Sold for the
three
months ended in Mar. 2026 was CHF144.0 Mil.
Hence, Evotec SE's Days Inventory for the
three
months ended in Mar. 2026 was 18.18.
The historical rank and industry rank for Evotec SE's Days Inventory or its related term are showing as below:
XSWX:EVT'
s Days Inventory Range Over the Past 10 Years
Min: 7.78 Med: 14.11 Max: 18.27
Current: 17.88
During the past 13 years, Evotec SE's highest Days Inventory was 18.27. The lowest was 7.78. And the median was 14.11.
XSWX:EVT's Days Inventory is ranked better than 98.58% of 916
companies
in the Drug Manufacturers industry
Industry Median: 164.43
vs XSWX:EVT: 17.88
Evotec SE's Days Inventory
increased
from Mar. 2025 (17.49) to Mar. 2026 (18.18).
It might indicate that Evotec SE's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Evotec SE's Inventory Turnover for the
three
months ended in Mar. 2026 was 5.02.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Evotec SE's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.20.
Evotec SE (XSWX:EVT) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Evotec SE's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Evotec SE's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Evotec SE Days Inventory Related Terms
Evotec SE Days Inventory Historical Data
* Premium members only.
The historical data trend for Evotec SE's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:EVT vs ZTS, UTHR, VTRS: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Days Inventory distribution charts can be found below:
* The bar in red indicates where Evotec SE's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (XSWX:EVT) has a Days Inventory of 18.18 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Evotec SE and its competitors. This is 29% above median its historical median of 14.11. Over the past decade, Evotec SE's Days Inventory has ranged from 7.78 to 18.27. According to the industry distribution chart, Evotec SE ranks #13 out of 916 companies in the Drug Manufacturers industry, placing it in the top 1.4%.
Is Evotec SE's Days Inventory too high?
Evotec SE's current Days Inventory of 18.18 is 29% above median its 10-year median of 14.11. Over the past 10 years, this metric has ranged from a low of 7.78 to a high of 18.27. The Drug Manufacturers industry median Days Inventory is 164.43. Evotec SE's value of 18.18 is 88.9% below this industry median. Based on the distribution chart, Evotec SE ranks #13 out of 916 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Evotec SE has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #13 out of 916 companies for Days Inventory. This places Evotec SE in the top 1% of its industry — outperforming the majority of peers. The industry median Days Inventory is 164.43. Evotec SE's value of 18.18 is 88.9% below this benchmark. Historically, Evotec SE's own Days Inventory has ranged from 7.78 to 18.27 over the past decade. While the company's 10-year median is 14.11 vs. the industry median of 164.43, Evotec SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.43, based on 916 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evotec SE's current Days Inventory of 18.18 is 88.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current Days Inventory is 18.18, which is 29% above median its own 10-year median of 14.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (XSWX:EVT) is currently considered Possible Value Trap. The stock's GF Value™ is CHF6.99, compared to a current price of CHF4.50 — trading 35.6% below its estimated fair value. The current Days Inventory is 18.18, which is 29% above median its 10-year median of 14.11 and 88.9% below the Drug Manufacturers industry median of 164.43. Evotec SE's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Evotec SE (XSWX:EVT), the current Days Inventory is 18.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (XSWX:EVT) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of CHF4.50 is trading 35.6% below its estimated GF Value™ of CHF6.99.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for XSWX:EVT:
Days Inventory: 18.18 (29% above median its 10-year median of 14.11)
GF Value™: CHF6.99 vs. price of CHF4.50 (35.6% below fair value)
Industry Position: 88.9% below the Drug Manufacturers median (#13 of 916)
No single metric tells the full story. See the XSWX:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
68GF Score
Get the complete analysis for XSWX:EVT
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EVT has been successfully added to your 
